A lectin HPLC method to enrich selectively-glycosylated peptides from complex biological samples.
Glycans are an important class of post-translational modifications. Typically found on secreted and extracellular molecules, glycan structures signal the internal status of the cell. Glycans on tumor cells tend to have abundant sialic acid and fucose moieties. We propose that these cancer-associated glycan variants be exploited for biomarker development aimed at diagnosing early-stage disease. Accordingly, we developed a mass spectrometry-based workflow that incorporates chromatography on affinity matrices formed from lectins, proteins that bind specific glycan structures. The lectins Sambucus nigra (SNA) and Aleuria aurantia (AAL), which bind sialic acid and fucose, respectively, were covalently coupled to POROS beads (Applied Biosystems) and packed into PEEK columns for high pressure liquid chromatography (HPLC). Briefly, plasma was depleted of the fourteen most abundant proteins using a multiple affinity removal system (MARS-14; Agilent). Depleted plasma was trypsin-digested and separated into flow-through and bound fractions by SNA or AAL HPLC. The fractions were treated with PNGaseF to remove N-linked glycans, and analyzed by LC-MS/MS on a QStar Elite. Data were analyzed using Mascot software. The experimental design included positive controls-fucosylated and sialylated human lactoferrin glycopeptides-and negative controls-high mannose glycopeptides from Saccharomyces cerevisiae-that were used to monitor the specificity of lectin capture. Key features of this workflow include the reproducibility derived from the HPLC format, the positive identification of the captured and PNGaseF-treated glycopeptides from their deamidated Asn-Xxx-Ser/Thr motifs, and quality assessment using glycoprotein standards. Protocol optimization also included determining the appropriate ratio of starting material to column capacity, identifying the most efficient capture and elution buffers, and monitoring the PNGaseF-treatment to ensure full deglycosylation. Future directions include using this workflow to perform mass spectrometry-based discovery experiments on plasma from breast cancer patients and control individuals.
Johansen
Eric
E
Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA.
Schilling
Birgit
B
Lerch
Michael
M
Niles
Richard K
RK
Liu
Haichuan
H
Li
Bensheng
B
Allen
Simon
S
Hall
Steven C
SC
Witkowska
H Ewa
HE
Regnier
Fred E
FE
Gibson
Bradford W
BW
Fisher
Susan J
SJ
Drake
Penelope M
PM
D001798:Blood Proteins / Q000302:isolation & purification; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006020:Glycopeptides / Q000097:blood / Q000302:isolation & purification*; D006801:Humans; D007781:Lactoferrin / Q000032:analysis; D037102:Lectins / Q000737:chemistry*; D037121:Plant Lectins / Q000737:chemistry*; D054788:Ribosome Inactivating Proteins / Q000737:chemistry*
D001798:Blood Proteins; D006020:Glycopeptides; D037102:Lectins; D037121:Plant Lectins; C050600:Sambucus nigra lectins; C064549:lectin, Aleuria aurantia; D054788:Ribosome Inactivating Proteins; D007781:Lactoferrin